May 8 (Reuters) - McKesson MCK.N forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its core drug distribution business.
Shares of the drug distributor rose 2% in extended trading.
The company said separation of the unit, which supplies surgical instruments and services, will allow it to focus on distribution of cancer drugs and other specialty medicines, which have shown higher growth and provide better margins.
Drug distributors in the United States are expanding their presence in the market for specialty medicines, which treat complex conditions such as cancer and rheumatoid arthritis, due to their high profit margins.
Texas-headquartered McKesson expects per-share profit in the range of $36.75 to $37.55 for fiscal 2026, compared with analysts' average estimate of $36.76, according to data compiled by LSEG.
The company reported fourth-quarter revenue of $90.8 billion, missing analysts' average estimate of $94.3 billion.
On an adjusted basis, McKesson earned $10.12 per share, compared with the estimates of $9.82 per share.
The drug distributor's U.S. pharmaceutical unit — its largest segment by revenue — recorded sales of $83.2 billion. That was 21% higher than the year earlier, driven by sales of cancer drugs, but missed analysts' estimate of $85.8 billion.
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
((Christy.Santhosh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。